images.jpg
Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies
August 27, 2020 09:30 ET | Connectyx Technologies Holdings Group, Inc
Company to Acquire Worldwide Rights for Development of IMT504  Boca Raton, FL, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the...
logo.png
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
July 08, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
logo.png
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
November 18, 2019 08:17 ET | Corbus Pharmaceuticals Holdings, Inc.
Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation...
logo.png
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
November 04, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET -                Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:...
logo.png
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates 
August 08, 2019 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Vivos Inc. Stock Symbol Reverts to RDGL University of Missouri Report Near Completion
July 29, 2019 07:00 ET | Vivos Inc.
Richland WA, July 29, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGL), stock symbol reverts back to RDGL effective with the open of trading on Monday, July 29. As previously disclosed, the D at...
Vivos Inc. Pilot Clinic Completes First IsoPet® Therapy
July 11, 2019 07:00 ET | Vivos Inc.
Richland WA, July 11, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGLD), Dr. Michelle Meyers, IsoPet® certified veterinarian practicing at Vista Veterinary Hospital, treated their first patient,...
Vivos Inc. Issues Corrective Press Release Regarding Reverse Stock Split
June 27, 2019 15:07 ET | Vivos Inc.
Richland, WA, June 27, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (the “Company”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy...
logo.png
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
May 01, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Logo new.jpg
Vivos Inc. Summarizes the Health of Canine Therapy Patients Treated with IsoPet
March 04, 2019 07:00 ET | Vivos Inc.
Richland WA, March 04, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTCPINK: RDGL), provides a summary of the previous update on dogs that have been treated to date in the canine soft tissue sarcoma...